Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD. [PDF]
Sabnis RW.
europepmc +1 more source
Allosteric activation of the glutamate receptor mGlu2 by the serotonin receptor 5-HT<sub>2A</sub>. [PDF]
Gai S +13 more
europepmc +1 more source
Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating Disorders. [PDF]
Sabnis RW.
europepmc +1 more source
Explainable Artificial Intelligence (xAI) for 5-HT<sub>2A</sub> Receptor Binding Affinity of New Psychoactive Substances. [PDF]
Schöning V +5 more
europepmc +1 more source
Lateral Habenula 5-HT₂A Receptors Mediate Social Deficits in a Valproic Acid-Induced Rodent Model of Autism Spectrum Disorder. [PDF]
Zhang C +7 more
europepmc +1 more source
Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HT<sub>2A/2C</sub> receptor activation with a major role of 5-HT<sub>2A</sub> receptors in the hippocampal CA3 subfield. [PDF]
Chagraoui A +11 more
europepmc +1 more source
Targeting Serotonin 5-HT<sub>2A</sub> Receptors in the Treatment of Aggression: from Antipsychotics to Psychedelics. [PDF]
Scheggi S +3 more
europepmc +1 more source

